Abstract：
Mesangial complement C3 deposits, reflecting alternative and possibly lectin pathway activation, are characteristic in biopsies of patients with IgA nephropathy (IgAN). A recent randomized controlled trial tested the efficacy and safety of iptacopan, a factor B inhibitor, in patients with IgAN. Iptacopan dose-dependently reduced proteinuria, and there was a pronounced decrease of urinary C5b-9. This offers the perspective of \"personalizing\" therapy, which would be a unique feature of this novel approach to IgAN. A phase III clinical trial (APPLAUSE-IgAN) is ongoing.
摘要：
系膜补体C3沉积物，反映了替代和可能的凝集素途径激活，是IgA肾病（IgAN）患者活检的特征。最近的一项随机对照试验测试了伊塔科潘的疗效和安全性，因子B抑制剂，IgAN患者。Iptacopan剂量依赖性地减少蛋白尿，尿C5b-9明显下降。这提供了“个性化”治疗的视角，这将是这种新颖的IgAN方法的独特之处。正在进行III期临床试验（APPLAUSE-IgAN）。
